Enlivex Therapeutics
ENLV

From March 31, 2025 to June 30, 2025 Restricted stock units vested

From December 31, 2024 to March 31, 2025 Issuance of shares for cash consideration of $203 net of $6 issuance costs Restricted stock units vested

From December 31, 2023 to December 31, 2024 Issuance of shares for cash consideration of $7,098 net of $646 issuance costs Restricted stock units vested Exercise of Warrants

From June 30, 2024 to September 30, 2024 Issuance of Ordinary Shares for cash consideration of $304 net of $9 of issuance costs Restricted stock units vested Exercise of Warrants Receivables from sale of Ordinary Shares

From December 31, 2023 to June 30, 2024 Issuance of shares for cash consideration of $43 net of $1 issuance costs Restricted stock units vested

Ordinary shares offered 2,060,000 shares by the company

From March 31, 2023 to June 30, 2023 Issuance of shares for cash consideration of $43 net of $1 issuance costs Restricted stock units vested

From December 31, 2021 to December 31, 2022 Exercise of options Restricted stock units vested

From DECEMBER 31, 2020 to DECEMBER 31, 2021 Issuance of shares and warrants for cash consideration of $57,629 net of $4,455 issuance costs Exercise of warrants Exercise of options

From June 30, 2021 to September 30, 2021 Exercise of options

1.Ordinary shares offered by the company 2,296,107 ordinary shares. 2.The number of ordinary shares outstanding is based on 13,463,771 shares outstanding as of September 30, 2020.

from DECEMBER 31, 2019 to DECEMBER 31, 2020 Issuance of shares and warrants for cash consideration of $26,968 net of $2,501 issuance costs Exercise of options Exercise of warrants

Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of an eight to one reverse split of its share capital. As previously reported, the reverse split was approved by Bioblast’s shareholders at a General Meeting of Shareholders of Bioblast held on December 27, 2018. Trading of the Company’s ordinary shares on the Nasdaq Capital Market will continue, on a split-adjusted basis, with the opening of the market on Wednesday, March 6, 2019, under the new CUSIP number M20156127. Immediately subsequent to the reverse split, there will be approximately 419,892 of the Company’s ordinary shares issued and outstanding.

from December 31, 2017 to December 31, 2018 Exercise of Options Issuance of Preferred Stock Series C for cash consideration of $5,350 net of $156 issuance costs

from December 31, 2016 to September 30, 2017 Exercise of stock options

The previously announced one-for-five reverse stock split of the common shares took effect as of today, September 25, 2017.Trading of the Company’s ordinary shares on the NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the market on Monday, September 25, 2017, under new CUSIP number M20156119. Immediately subsequent to the reverse split, there will be approximately 3,342,261 of the Company’s ordinary shares issued and outstanding.

From December 31, 2015 to June 30, 2016 Issuance of Ordinary shares and warrants for Ordinary shares in a registered direct offering ($3.10 per share), net of issuance costs of $611

from December 31, 2013 to July 31, 2014 Issuance of Ordinary shares, net ($0.95 per share) Issuance of Ordinary shares upon private placement, net ($6.07 per share) Issuance of Ordinary shares upon initial public offering, net ($11 per share)

from December 31, 2012 to December 31, 2013 Conversion of Preferred A shares into Ordinary shares Issuance of Ordinary shares, net ($0.95 per share)